Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117451

Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.

Y Zhang, Y Deng, T Luther, M Müller, R Ziegler, R Waldherr, D M Stern, and P P Nawroth

Department of Medicine, University of Heidelberg, Germany.

Find articles by Zhang, Y. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Deng, Y. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Luther, T. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Müller, M. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Ziegler, R. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Waldherr, R. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Stern, D. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Heidelberg, Germany.

Find articles by Nawroth, P. in: JCI | PubMed | Google Scholar

Published September 1, 1994 - More info

Published in Volume 94, Issue 3 on September 1, 1994
J Clin Invest. 1994;94(3):1320–1327. https://doi.org/10.1172/JCI117451.
© 1994 The American Society for Clinical Investigation
Published September 1, 1994 - Version history
View PDF
Abstract

Meth-A sarcoma cells were stable transfected to overexpress (sense construct) or underexpress (antisense construct) tissue factor. In vitro, there was no difference in plating efficiency or growth between these cell lines. In vivo, tumor cells transfected to overexpress tissue factor grew more rapidly, and established larger and more vascularized tumors than control transfectants. Antisense transfectants grew the slowest and were the least vascularized. Anticoagulation of mice with warfarin did not alter the difference between these tumor lines. Tumor cells over-expressing tissue factor released more (compared with control transfectants) mitogenic activity for endothelial cells in parallel with enhanced transcription of vascular permeability factor/vascular endothelial cell growth factor (VEGF/VPF), and diminished transcription of thrombospondin (TSP2), a molecule with anti-angiogenic properties. Antisense tissue factor transfectants, while releasing the lowest amount of mitogenic activity, had increased thrombospondin and decreased VEGF/VPF transcription compared with control transfectants or wild-type cells. Experiments with these sense, antisense, truncated sense, or vector tumor lines gave comparable results in complete medium, serum free medium or in the presence of hirudin, indicating that the activation of the coagulation mechanism was not likely to be responsible for changes in tumor cell properties. These results suggest that tissue factor regulates angiogenic properties of tumor cells by altering the production of growth regulatory molecules of endothelium by a mechanism distinct from tissue factor activation of the coagulation mechanism.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1320
page 1320
icon of scanned page 1321
page 1321
icon of scanned page 1322
page 1322
icon of scanned page 1323
page 1323
icon of scanned page 1324
page 1324
icon of scanned page 1325
page 1325
icon of scanned page 1326
page 1326
icon of scanned page 1327
page 1327
Version history
  • Version 1 (September 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts